Salud financiera de hoja de balance de Sarepta Therapeutics
Salud financiera controles de criterios 4/6
Sarepta Therapeutics tiene un patrimonio de accionistas total de $1.2B y una deuda total de $1.2B, lo que sitúa su ratio deuda-patrimonio en 100.5%. Sus activos y pasivos totales son $3.6B y $2.4B respectivamente. El BAIT de Sarepta Therapeutics es de $81.0M, por lo que su ratio de cobertura de intereses es de -6.6. Tiene efectivo e inversiones a corto plazo que ascienden a $1.2B.
Información clave
100.5%
Ratio deuda-patrimonio
US$1.23b
Deuda
| Ratio de cobertura de intereses | -6.6x |
| Efectivo | US$1.20b |
| Patrimonio | US$1.22b |
| Total pasivo | US$2.38b |
| Activos totales | US$3.60b |
Actualizaciones recientes sobre salud financiera
Is Sarepta Therapeutics (NASDAQ:SRPT) A Risky Investment?
Oct 20
Is Sarepta Therapeutics (NASDAQ:SRPT) Using Debt In A Risky Way?
Apr 15Does Sarepta Therapeutics (NASDAQ:SRPT) Have A Healthy Balance Sheet?
Nov 29Is Sarepta Therapeutics (NASDAQ:SRPT) Using Too Much Debt?
Aug 08Is Sarepta Therapeutics (NASDAQ:SRPT) Using Too Much Debt?
Apr 30Is Sarepta Therapeutics (NASDAQ:SRPT) Weighed On By Its Debt Load?
Jan 17Recent updates
Sarepta Therapeutics (NASDAQ:SRPT) Is Posting Healthy Earnings, But It Is Not All Good News
Nov 13Is Sarepta Therapeutics (NASDAQ:SRPT) A Risky Investment?
Oct 20The Play On Sarepta Therapeutics
Sep 26Sarepta Therapeutics Muscles Up In DMD Race
Sep 19Sarepta Therapeutics' Pullback After Recent FDA Approval A Buying Opportunity
Jul 24Revenues Not Telling The Story For Sarepta Therapeutics, Inc. (NASDAQ:SRPT) After Shares Rise 28%
Jul 05Sarepta Therapeutics: Navigating Elevidys Upside Potential
Jun 17Sarepta Therapeutics' (NASDAQ:SRPT) Earnings Aren't As Good As They Appear
May 08Results: Sarepta Therapeutics, Inc. Beat Earnings Expectations And Analysts Now Have New Forecasts
May 05Is Sarepta Therapeutics (NASDAQ:SRPT) Using Debt In A Risky Way?
Apr 15Sarepta Therapeutics: Growth Trajectory Alters Trading Strategy
Apr 11Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
Mar 02Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Shares Fly 29% But Investors Aren't Buying For Growth
Feb 06Sarepta Therapeutics: Navigating Elevidys Towards FDA Approval
Jan 22Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Shares Could Be 50% Below Their Intrinsic Value Estimate
Jan 10There's No Escaping Sarepta Therapeutics, Inc.'s (NASDAQ:SRPT) Muted Revenues
Dec 20Does Sarepta Therapeutics (NASDAQ:SRPT) Have A Healthy Balance Sheet?
Nov 29Is Sarepta Therapeutics (NASDAQ:SRPT) Using Too Much Debt?
Aug 08Is Sarepta Therapeutics (NASDAQ:SRPT) Using Too Much Debt?
Apr 30Is Sarepta Therapeutics (NASDAQ:SRPT) Weighed On By Its Debt Load?
Jan 17Sarepta Therapeutics seeks FDA accelerated approval for muscle wasting therapy SRP-9001
Sep 29Sarepta Therapeutics announces offering of $1B of convertible senior notes due 2027
Sep 12Sarepta says FDA lifted clinical hold on Duchenne candidate
Sep 06Is Sarepta Therapeutics (NASDAQ:SRPT) Weighed On By Its Debt Load?
Aug 22Sarepta inks licensing deal with Broad Institute for certain adeno-associated viruses
Aug 08Sarepta stock soars 19% on plans for US filing for gene therapy for neuromuscular disorder
Jul 29Análisis de la situación financiera
Pasivos a corto plazo: Los activos a corto plazo ($2.7B) de SRPT superan a sus pasivos a corto plazo ($699.5M).
Pasivo a largo plazo: Los activos a corto plazo de SRPT ($2.7B) superan a sus pasivos a largo plazo ($1.7B).
Historial y análisis de deuda-patrimonio
Nivel de deuda: El ratio deuda neta-patrimonio (2.4%) de SRPT se considera satisfactorio.
Reducción de la deuda: El ratio deuda-patrimonio de SRPT ha crecido de 43.9% a 100.5% en los últimos 5 años.
Cobertura de la deuda: El flujo de caja operativo de SRPT es negativo, por lo que la deuda no está bien cubierta.
Cobertura de intereses: SRPT gana más intereses de los que paga, por lo que la cobertura de pagos de intereses no es preocupante.